In the article titled "Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice" \[[@B1]\], there were the following errors.

\(i\) In the Statistical Analysis section, "The computed OR were adjusted for age and pretreatment hemoglobin for the endpoints related to hemoglobin increase and for age and pretreatment transferrin saturation for the endpoint related to the increase of transferrin saturation" should be corrected to "The computed OR were adjusted for age and pre-treatment hemoglobin for the endpoints related with hemoglobin increase, and for age and pre-treatment ferritin for the endpoint related with the increase of transferrin saturation."

\(ii\) There were multiple errors in the Efficacy Endpoints section. The corrected section is as follows.

"The primary (i.e., hemoglobin increase ≥2 g/dL) and secondary (i.e., hemoglobin increase ≥3 g/dL and transferrin saturation \>20%) efficacy endpoints, following intravenous FCM treatment, are shown in Table 3. After 6 weeks, hemoglobin increase ≥2 g/dL was attained by 41% of all patients, 49% in the IDA group, 40% in the diseases of the digestive system group, 55% in the diseases of the genitourinary system group, 26% in the neoplasms group, and 29% in the diseases of the circulatory system group. Moreover, our analysis indicated that patients with IDA or diseases of the genitourinary system presented significant decreased odds of clinical failure (OR: 0.07, 95% CI 0.03-0.15 or OR: 0.46, 95% CI 0.25-0.87, respectively), whereas patients with diseases of the circulatory system showed about three times higher odds of clinical failure (OR: 3.34, 95% CI 1.31-8.98). Regarding cumulative FCM treatment dose, we found significant decreased odds of clinical failure in patients who received doses ranging from 501 to 1000 mg (OR: 0.34, 95% CI 0.18-0.62) or 1001-3000 mg doses (OR: 0.19, 95% CI 0.07-0.49), compared to patients who received doses of 500 mg (Table 3).

Hemoglobin increase of ≥3 g/dL after 6 weeks after FCM dose was attained by 20% of all patients, 25% of the patients in the IDA group, 22% in the diseases of the digestive system group, 26% in the diseases of the genitourinary system group, 11% in the neoplasms group, and 16% in the diseases of the circulatory system group. Furthermore, our analysis indicated that patients with IDA presented significant lower odds of clinical failure (OR: 0.07, 95% CI 0.01-0.22). Concerning total FCM treatment dose, our analysis showed significant lower odds of clinical failure in patients who received doses ranging from 501 to 1000 mg (OR: 0.36, 95% CI 0.12-0.92) or 1001-3000 mg doses (OR: 0.23, 95% CI 0.06-0.73), compared to patients who received doses of 500 mg (Table 3).

Finally, transferrin saturation \>20% after 6 weeks after FCM dose was attained by 63% of all patients, 62% of patients in the IDA group, 69% of patients in the iron deficiency without anemia group, 63% in the diseases of the digestive system group, 68% in the diseases of the genitourinary system group, 67% in the neoplasms group, and 47% in the diseases of the circulatory system group. Our analysis indicated significant lower odds of clinical failure in patients who received doses ranging from 501 to 1000 mg (OR: 0.57, 95% CI 0.36-0.88) or 1001-3000 mg doses (OR: 0.25, 95% CI 0.10-0.55), compared to patients who received doses of 500 mg (Table 3)."

\(iii\) There were errors in Table 3. The corrected table is shown below.

\(iv\) In the Discussion section, "For patients with IDA, no differences in treatment efficacy were found for hemoglobin increase of ≥2 g/dL and transferrin saturation \> 20%, compared with patients without IDA. However, we found a significant difference in hemoglobin increase of ≥3 g/dL" should be corrected to "For patients with IDA, no differences in treatment efficacy were found for transferrin saturation \>20%, compared with patients without IDA. However, we found significant differences in both hemoglobin-related efficacy endpoints."
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###### 

The underlying patient-level data and a script with all the logistic regression models adjusted to generate the Odds Ratio and respective confidence intervals for Table 3 are included as Supplementary Materials.

###### 

Click here for additional data file.

###### 

Odds ratio of clinical failure in primary and secondary efficacy endpoints for intravenous FCM treatment.

                                         Hemoglobin increase ≥2 g/dL   Hemoglobin increase ≥3 g/dL   Transferrin saturation \>20%^a^                                                            
  -------------------------------------- ----------------------------- ----------------------------- ---------------------------------- ----- --------- ---------------------- ----- ---------- ----------------------
  Characteristic                         N                             n (%)                         OR (95% CI)                        N     n (%)     OR (95% CI)            N     n (%)      OR (95% CI)
  All                                    459                           190 (41)                      \-                                 459   94 (20)   \-                     450   285 (63)   \-
  Male                                   101                           35 (35)                       1.7 (0.94-3.13)                    101   20 (20)   1.01 (0.50-2.10)       98    54 (55)    1.45 (0.91-2.31)
  Iron deficiency anemia                 373                           184 (49)                      **0.07 (0.03-0.15)**               373   92 (25)   **0.07 (0.01-0.22)**   373   232 (62)   1.29 (0.77-2.23)
  Iron deficiency without anemia         77                            \-                            \-                                 77    \-        \-                     77    53 (69)    0.77 (0.45-1.30)
  Diseases of the digestive system       199                           79 (40)                       0.88 (0.54-1.42)                   199   43 (22)   0.57 (0.31-1.04)       195   123 (63)   0.95 (0.63-1.4)
  Diseases of the genitourinary system   121                           67 (55)                       **0.46 (0.25-0.87)**               121   31 (26)   1.22 (0.59-2.54)       52    82 (68)    0.88 (0.52-1.48)
  Neoplasms                              47                            12 (26)                       2.19 (0.98-5.19)                   47    5 (11)    1.63 (0.57-5.72)       45    30 (67)    0.70 (0.35-1.38)
  Diseases of the circulatory system     38                            11 (29)                       **3.34 (1.31-8.98)**               38    6 (16)    2.1 (0.72-6.86)        38    18 (47)    1.82 (0.91-3.65)
  Other diseases                         54                            21 (39)                       0.94 (0.45-1.97)                   54    9 (17)    1.12 (0.47-2.90)       52    32 (62)    1.13 (0.61-2.06)
  Cumulative FCM treatment dose^b^                                                                                                                                                               
  500 mg                                 122                           18 (15)                       \-                                 122   5 (4)     \-                     114   58 (51)    \-
  501--1000 mg                           290                           141 (49)                      **0.34 (0.18-0.62)**               290   70 (24)   **0.36 (0.12-0.92)**   289   189 (65)   **0.57 (0.36-0.88)**
  1001--3000 mg                          47                            31 (66)                       **0.19 (0.07-0.49)**               47    19 (40)   **0.23 (0.06-0.73)**   47    38 (81)    **0.25 (0.10-0.55)**

Significant odds ratio in boldface.

CI: confidence interval; FCM: ferric carboxymaltose; N: total number of subjects; n: number of subjects achieving the endpoint; OR: odds ratio.

 ^a^ Only patients who had transferrin saturation \<20% before treatment were considered for this endpoint. Therefore, all data presented for this endpoint only considers those subjects with iron deficiency.

 ^b^ Reference group: cumulative iron dose of 500 mg.
